GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmena SA (WAR:PHR) » Definitions » Notes Receivable

Pharmena (WAR:PHR) Notes Receivable : zł0.00 Mil (As of Mar. 2025)


View and export this data going back to 2008. Start your Free Trial

What is Pharmena Notes Receivable?

Pharmena's Notes Receivable for the quarter that ended in Mar. 2025 was zł0.00 Mil.


Pharmena Notes Receivable Historical Data

The historical data trend for Pharmena's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmena Notes Receivable Chart

Pharmena Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pharmena Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Pharmena Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Pharmena Notes Receivable Related Terms

Thank you for viewing the detailed overview of Pharmena's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmena Business Description

Traded in Other Exchanges
N/A
Address
Ulica Wolczanska 178, Lodz, POL, 90-530
Pharmena SA produces cosmeceuticals and pharmaceuticals. The company's activity focuses on three areas such as research in the USA and Canada on the application of selected pyridinium salts in medicine in order to develop an anti-atherosclerosis drug on a global scale, Production and sales of innovative patented dermocosmetics and introduction into the market of an innovative dietary supplement for atherosclerosis prophylaxis. Its products include Menavitin, Dermena, Allerco and Thermi.